A novel, topical, nonsteroidal, TRPV1 antagonist, PAC-14028 cream improves skin barrier function and exerts anti-inflammatory action through modulating epidermal differentiation markers and suppressing Th2 cytokines in atopic dermatitis.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of dermatological science"
DOI: 10.1016/j.jdermsci.2018.04.017
Abstract: BACKGROUND Although it is established that epidermal barrier disturbance and immune dysfunction resulting in IgE sensitization are critical factors in the development of cutaneous inflammation, the pathogenesis and targeted therapy of atopic dermatitis (AD)-specific pathways… read more here.
Keywords: barrier; 14028 cream; barrier function; dermatitis ... See more keywords
Novel therapeutic approach with PAC‐14028 cream, a TRPV1 antagonist, for patients with mild‐to‐moderate atopic dermatitis
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Dermatology"
DOI: 10.1111/bjd.17777
Abstract: This issue of the BJD includes a potentially important study concerning a new topical treatment for atopic dermatitis (AD), which is characterized by significant pruritus, a key feature of AD. While the precise mechanism of… read more here.
Keywords: trpv1; dermatology; trpv1 antagonist; treatment ... See more keywords
用于特应性皮炎的 PAC‐14028 乳膏
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Dermatology"
DOI: 10.1111/bjd.17814
Abstract: 这项来自韩国的研究显示,一种名为 PAC‐14028 的不含类固醇的乳膏在治疗湿疹症状时与当前市售乳膏一样有效,且副作用更少。湿疹是最常见的皮肤病之一。现有局部(外用于皮肤)治疗在治疗湿疹症状方面可以非常有效。但是,它们可导致不良副作用,如瘙痒和烧灼感,进而使患者中止他们的治疗。对 194 名轻中度湿疹成人进行了这项研究。参与者被分为 4 个组,接受对照乳膏或 3 种不同浓度(0.1%、0.3% 或 1.0%)新治疗 PAC‐14028 乳膏给药。参与者每天两次外用乳膏,共计 8 周。主要使用研究者整体评估 (IGA) 测量结果。这是一个基于典型症状评估患者湿疹严重程度的视觉量表。8 周后,最高浓度 PAC‐14028 乳膏组中有 57.5% 患者的 IGA 评分显示他们的湿疹症状完全根除或降低至几乎清除的水平。对于对照乳膏,第 8 周的 IGA 成功率为 15%,而 0.1%、0.3% 和 1.0% PAC‐14028 乳膏分别为 43%、38%… read more here.
Keywords: iga; dermatology; pac; 14028 pac ... See more keywords